StockData
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. (MCRB) shareholders

MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$1.41+0.00 (0.00%)

Close on Nov 17, 2026Market cap $14.02MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
22.9%
2M of 10M shares
Institutional holders
36
8 new, 5 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 16 sales
Net sold $10.84K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
FMR LLC
Joint filing with Abigail P. Johnson (12.80%)
21,811,69712.80%13G (passive) amendmentDec 31, 2024
Nestlé S.A.21,781,753–13D (active) amendmentSep 30, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of MCRBValueChange% of portfolio
Flagship Pioneering Inc.1,155,85011.63%$9.12M–0.59%
Vanguard Capital Management LLC287,7762.89%$2.27M−6,3670.00%
Marshall Wace, Llp172,2451.73%$1.36M+32,7060.00%
Vontobel Holding Ltd.122,9751.24%$970.27K−15,4930.00%
BlackRock, Inc.111,0001.12%$875.79K+8,9740.00%
Geode Capital Management, LLC79,9740.80%$631.30K+5,1390.00%
Susquehanna International Group, Llp58,3280.59%$460.21K−47,0110.00%
Vanguard Fiduciary Trust Co48,6850.49%$384.13K+9,0420.00%
State Street Corp33,9010.34%$267.48K–0.00%
Lion Point Capital, LP31,5700.32%$249.09K–1.19%
Charles Schwab Investment Management Inc31,0490.31%$244.98K−5810.00%
American Century Companies Inc28,3130.28%$223.39K−34,0030.00%
XTX Topco Ltd20,7320.21%$163.58KNew0.00%
Goldman Sachs Group Inc15,2290.15%$120.16KNew0.00%
Northern Trust Corp14,7650.15%$116.50K–0.00%
Invesco Ltd.12,9740.13%$102.37K−1,5730.00%
Morgan Stanley12,1380.12%$95.77K−9,5620.00%
Citadel Advisors LLC10,5040.11%$82.88KNew0.00%
Simplex Trading, LLC4,5980.05%$36.28K+1,5280.00%
SBI Securities Co., Ltd.4,1820.04%$33.00K+7000.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026362M22.9%8 / 712 / 50M0M
Q1 2026332M23.2%5 / 108 / 70M0M
Q4 2025362M24.6%9 / 147 / 50M0M
Q3 2025322M21.4%9 / 117 / 100M0M
Q2 2025332M23.1%32 / 01 / 32M0M
Q1 202540M0.1%4 / 00 / 00M0M
Q1 202100M0.0%0 / 00 / 10M0M
Q4 202010M0.0%1 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

32 funds held MCRB in Q1 2026, 68% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of MCRBValue% of fundAs of
Vanguard Total Stock Market Index Fund206,1702.07%$1.63M0.00%Jun 30, 2026
Vanguard Extended Market Index Fund75,8490.76%$598.45K0.00%Jun 30, 2026
Avantis U.S. Small Cap Value ETF37,3640.38%$273.50K0.00%May 31, 2026
Schwab U.S. Small-Cap ETF31,0770.31%$227.48K0.00%May 31, 2026
Fidelity Extended Market Index Fund26,3350.26%$192.77K0.00%May 31, 2026
iShares Micro-Cap ETF25,3890.26%$200.32K0.01%Jun 30, 2026
Fidelity Total Market Index Fund13,8700.14%$101.53K0.00%May 31, 2026
Invesco RAFI US 1500 Small-Mid ETF12,9140.13%$62.37K0.00%Jul 31, 2026
Fidelity Series Total Market Index Fund10,1430.10%$74.25K0.00%May 31, 2026
Goldman Sachs Absolute Return Tracker Fund10,0650.10%$79.41K0.00%Jun 30, 2026
U.S. Micro Cap Portfolio7,6620.08%$37.01K0.00%Jul 31, 2026
Ultra-Small Company Market Fund7,5000.08%$59.18K0.04%Jun 30, 2026
WisdomTree U.S. SmallCap Fund7,0580.07%$55.69K0.01%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund5,6660.06%$41.48K0.00%May 31, 2026
Avantis U.S. Small Cap Equity ETF5,2770.05%$38.63K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Richard N. KenderSee Remarks, Director63,4920.64%Jul 10, 2026
Thomas DesRosierSee Remarks8,2580.08%Nov 17, 2026
Kelly BradySee Remarks8,7750.09%Nov 17, 2026
Matthew R. HennSee Remarks8,1320.08%Nov 17, 2026
Marella ThorellSee Remarks––Jul 10, 2026
Teresa L. YoungSee Remarks8,5570.09%Feb 18, 2026
Moltke Lisa vonSee Remarks39,8750.40%Feb 19, 2025
Eric D. ShaffDirector12,9360.13%Nov 17, 2026
Stephen BerensonDirector3,5890.04%Jul 10, 2026
Robert L. RosielloDirector––Jul 10, 2026
Dennis A. AusielloDirector––Jul 10, 2026
Willard H. DereDirector31,7460.32%Jul 10, 2026
Claire FraserDirector––Jul 10, 2026
Kurt GravesDirector––Jul 10, 2026
Paul BiondiDirector47,6190.48%Apr 11, 2025
Hans-Juergen WoerleDirector––Feb 6, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Kelly Brady
See Remarks
Nov 16, 2026Sale(10b5-1 plan)−85$1.38$1178,775
Thomas DesRosier
See Remarks
Nov 16, 2026Sale(10b5-1 plan)−103$1.38$1428,258
Eric D. Shaff
Director
Nov 16, 2026Sale(10b5-1 plan)−287$1.38$39612,936
Matthew R. Henn
See Remarks
Nov 16, 2026Sale(10b5-1 plan)−101$1.38$1398,132
Kelly Brady
See Remarks
Nov 15, 2026Option exercise+181––8,860
Thomas DesRosier
See Remarks
Nov 15, 2026Option exercise+244––8,361
Eric D. Shaff
Director
Nov 15, 2026Option exercise+724––13,223
Matthew R. Henn
See Remarks
Nov 15, 2026Option exercise+238––8,233
Kelly Brady
See Remarks
Aug 17, 2026Sale(10b5-1 plan)−64$4.55$2918,679
Thomas DesRosier
See Remarks
Aug 17, 2026Sale(10b5-1 plan)−82$4.55$3738,117
Eric D. Shaff
Director
Aug 17, 2026Sale(10b5-1 plan)−263$4.55$1.20K12,499
Matthew R. Henn
See Remarks
Aug 17, 2026Sale(10b5-1 plan)−81$4.55$3697,995
Kelly Brady
See Remarks
Aug 15, 2026Option exercise+181––8,743
Thomas DesRosier
See Remarks
Aug 15, 2026Option exercise+245––8,199
Eric D. Shaff
Director
Aug 15, 2026Option exercise+722––12,762
Matthew R. Henn
See Remarks
Aug 15, 2026Option exercise+238––8,076
Thomas DesRosier
See Remarks
May 18, 2026Sale(10b5-1 plan)−79$7.53$5957,954
Kelly Brady
See Remarks
May 18, 2026Sale−59$7.53$4448,562
Eric D. Shaff
Director
May 18, 2026Sale(10b5-1 plan)−259$7.53$1.95K12,040
Matthew R. Henn
See Remarks
May 18, 2026Sale(10b5-1 plan)−77$7.53$5807,838
Thomas DesRosier
See Remarks
May 15, 2026Option exercise+244––8,033
Kelly Brady
See Remarks
May 15, 2026Option exercise+180––8,621
Eric D. Shaff
Director
May 15, 2026Option exercise+722––12,299
Matthew R. Henn
See Remarks
May 15, 2026Option exercise+238––7,915
Teresa L. Young
See Remarks
Feb 15, 2026Sale(10b5-1 plan)−75$8.47$6358,557
Teresa L. Young
See Remarks
Feb 15, 2026Option exercise+231––8,632
Thomas DesRosier
See Remarks
Feb 15, 2026Option exercise+244––7,867
Thomas DesRosier
See Remarks
Feb 15, 2026Sale(10b5-1 plan)−78$8.47$6617,789
Eric D. Shaff
Director
Feb 15, 2026Sale(10b5-1 plan)−259$8.47$2.19K11,577
Eric D. Shaff
Director
Feb 15, 2026Option exercise+723––11,836
Matthew R. Henn
See Remarks
Feb 15, 2026Sale(10b5-1 plan)−89$8.47$7547,677
Matthew R. Henn
See Remarks
Feb 15, 2026Option exercise+239––7,766
Thomas DesRosier
See Remarks
Nov 15, 2025Sale(10b5-1 plan)−76$17.30$1.31K7,623
Thomas DesRosier
See Remarks
Nov 15, 2025Option exercise+112––7,699
Thomas DesRosier
See Remarks
Nov 15, 2025Option exercise+132––7,587
Teresa L. Young
See Remarks
Nov 15, 2025Option exercise+132––9,345
Teresa L. Young
See Remarks
Nov 15, 2025Option exercise+98––9,443
Teresa L. Young
See Remarks
Nov 15, 2025Option exercise+3,998––9,213
Teresa L. Young
See Remarks
Nov 15, 2025Sale(10b5-1 plan)−1,042$17.30$18.03K8,401
Matthew R. Henn
See Remarks
Nov 15, 2025Option exercise+140––8,686
Matthew R. Henn
See Remarks
Nov 15, 2025Option exercise+3,998––8,546
Matthew R. Henn
See Remarks
Nov 15, 2025Option exercise+98––8,784
Matthew R. Henn
See Remarks
Nov 15, 2025Sale(10b5-1 plan)−1,257$17.30$21.75K7,527
Eric D. Shaff
Director
Nov 15, 2025Option exercise+390––10,999
Eric D. Shaff
Director
Nov 15, 2025Option exercise+331––11,330
Eric D. Shaff
Director
Nov 15, 2025Sale(10b5-1 plan)−217$17.30$3.75K11,113
Teresa L. Young
See Remarks
Aug 18, 2025Sale(10b5-1 plan)−59$16.65$9825,215
Thomas DesRosier
See Remarks
Aug 18, 2025Sale(10b5-1 plan)−76$16.65$1.27K7,455
Eric D. Shaff
Director
Aug 18, 2025Sale(10b5-1 plan)−217$16.65$3.61K10,609
Matthew R. Henn
See Remarks
Aug 18, 2025Sale(10b5-1 plan)−73$16.65$1.22K4,548
Teresa L. Young
See Remarks
Aug 15, 2025Option exercise+97––5,274
Teresa L. Young
See Remarks
Aug 15, 2025Option exercise+133––5,177
Thomas DesRosier
See Remarks
Aug 15, 2025Option exercise+133––7,420
Thomas DesRosier
See Remarks
Aug 15, 2025Option exercise+111––7,531
Eric D. Shaff
Director
Aug 15, 2025Option exercise+391––10,493
Eric D. Shaff
Director
Aug 15, 2025Option exercise+333––10,826
Matthew R. Henn
See Remarks
Aug 15, 2025Option exercise+141––4,524
Matthew R. Henn
See Remarks
Aug 15, 2025Option exercise+97––4,621
Teresa L. Young
See Remarks
May 16, 2025Sale(10b5-1 plan)−63$7.28$4595,044
Matthew R. Henn
See Remarks
May 16, 2025Sale(10b5-1 plan)−77$7.28$5614,383

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
3.53%
0M shares short
Days to cover
4.3
At 0M shares a day
Change since last report
+9.6%
From 0M shares
Short volume, 20 days
49.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Seres Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 10,817 shares on Oct 2, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Teresa L. Young
Officer
May 19, 2026167$1.28KMay 19, 2026Restricted Stock
Teresa L. Young
Officer
Mar 17, 20268,553$77.97KMar 17, 2026Restricted and Performance Shares

See a number that looks wrong?